We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex, AstraZeneca, Ferring, GlaxoSmithKline, J & J Innovation, Pfizer, Shionogi) who are committed to collaboration and research investment in Cambridge academic institutes. “The renewal of this Consortium is a fantastic opportunity for the Milner and Cambridge researchers to make significant progress towards our goal of transforming pioneering science into therapies. It reflects the strong commitment of these companies to innovative collaborations with academics that add value through combined resource and complementary expertise. It is particularly exciting that this coincides with the opening of the Milner Therapeutics Institute this summer, providing a physical hub for these partnerships” says our Director Tony Kouzarides.